Health Trials

Primary Plasma Cell Leukemia

3

Review clinical trials related to Primary Plasma Cell Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma

Participants needed: 54
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUpdated: Apr 16, 2025Locations: 1
Eligibility criteria

Patients must have newly diagnosed ultra high-risk disease, as defined by one of... [+4]

No evidence of high-risk disease. [+17]

Read more
Status: Recruiting

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.

Participants needed: 43
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Hellenic Society of HematologyUpdated: Oct 10, 2024Locations: 7
Eligibility criteria

Age between 18 and 80 years (inclusive) at the time of signing the informed cons... [+61]

Read more
Status: Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.

Participants needed: 166
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CARsgen Therapeutics Co., Ltd.Updated: Mar 27, 2024
Eligibility criteria

Voluntarily signed consent; [+14]

Any significant condition(s), laboratory abnormality or psychiatric illness that... [+20]

Read more